Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil

Página do item simplificado
dc.contributor.authorDalcolmo, Margareth
dc.contributor.authorGayoso, Regina
dc.contributor.authorSotgiu, Giovanni
dc.contributor.authorD’Ambrosio, Lia
dc.contributor.authorRocha, Jorge L.
dc.contributor.authorBorga, Liamar
dc.contributor.authorFandinho, Fatima
dc.contributor.authorBraga, Jose U.
dc.contributor.authorGalesi, Vera M.N.
dc.contributor.authorBarreira, Draurio
dc.contributor.authorSanchez, Denise A.
dc.contributor.authorDockhorn, Fernanda
dc.contributor.authorCentis, Rosella
dc.contributor.authorCaminero, Jose A.
dc.contributor.authorMigliori, Giovanni B.
dc.date.accessioned2024-11-21T18:51:16Z
dc.date.available2024-11-21T18:51:16Z
dc.date.issued2017
dc.description.abstractAlthough clofazimine is used to treat multidrug-resistant tuberculosis (MDR-TB), there is scant information on its effectiveness and safety. The aim of this retrospective, observational study was to evaluate these factors as well as the tolerability of clofazimine in populations in Brazil, where it was administered at a daily dose of 100 mg·day−1 (body weight ⩾45 kg) as part of a standardised MDR-TB treatment regimen until 2006 (thereafter pyrazinamide was used). All MDR-TB patients included in the Sistema de Informação de Tratamentos Especiais da Tuberculose (SITETB) individual electronic register were analysed. The effectiveness of clofazimine was assessed by comparing the treatment outcomes of patients undergoing clofazimine-containing regimens against those undergoing clofazimine-free regimens and its safety by describing clofazimine-attributed adverse events. A total of 1446 patients were treated with clofazimine-containing regimens and 1096 with pyrazinamide- containing regimens. Although success rates were similar in patients treated with clofazimine versus those treated with pyrazinamide (880 out of 1446, 60.9%, versus 708 out of 1096, 64.6%; p=0.054), clofazimine-treated cases exhibited higher death rates due to tuberculosis than pyrazinamide-treated ones (314 out of 1446, 21.7%, versus 120 out of 1096, 10.9%) but fewer failures (78 out of 1446, 5.4%, versus 95 out of 1096, 8.7%) and less loss to follow-up (144 out of 1446, 10.0%, versus 151 out of 1096, 13.8%). No relevant differences were detected when comparing adverse events in patients treated with clofazimine-containing regimens to those treated with clofazimine-free regimens. However, the incidence of side-effects was less than previously reported (gastro-intestinal complaints: 10.5%; hyper-pigmentation: 50.2%; neurological disturbances: 9–13%).
dc.identifier.citationDalcolmo M, Gayoso R, Sotgiu G, et al. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. Eur Respir J 2017; 49: 1602445 doi: 10.1183/13993003.02445-2016.
dc.identifier.otherDOI: 10.1183/13993003.02445-2016
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/616
dc.language.isoen
dc.publisherEuropean Respiratory Journal
dc.titleEffectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Dalcolmo M et al_Eur Respir J.pdf
Tamanho:
12.57 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar
Coleções
Produção Docente